Attached files
file | filename |
---|---|
8-K - FORM 8-K - Unilife Corp | c24798e8vk.htm |
EX-5.1 - EXHIBIT 5.1 - Unilife Corp | c24798exv5w1.htm |
EX-1.1 - EXHIBIT 1.1 - Unilife Corp | c24798exv1w1.htm |
EX-99.1 - EXHIBIT 99.1 - Unilife Corp | c24798exv99w1.htm |
Exhibit 99.2
For Immediate Release
UNILIFE CORPORATION ANNOUNCES PRICING OF OFFERING
OF 8,250,000 SHARES OF COMMON STOCK
OF 8,250,000 SHARES OF COMMON STOCK
York, PA, November 16, 2011- Unilife Corporation (NASDAQ: UNIS / ASX: UNS) (Unilife or the
Company) today announced the pricing of its underwritten registered public offering of 8,250,000
shares of common stock at a public offering price of $4.35 per share. All of the shares in the
offering are to be sold by Unilife. In connection with the offering, the Company also granted the
underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock to
cover over-allotments, if any.
The net proceeds of the offering to the Company, after deducting the underwriting discount and
estimated offering expenses, are expected to be approximately $33,808,125, exclusive of any
proceeds attributable to the underwriters possible exercise of their over-allotment option.
Unilife expects to use the net proceeds from this offering to fund the continued development and
commercial supply of its diversified portfolio of advanced drug delivery systems, the expansion of
its workforce to support anticipated customer demands, and for working capital and other general
corporate purposes. The offering is expected to close on November 21, 2011 and is subject to
customary closing conditions.
Jefferies & Company, Inc. is acting as sole book-running manager for the offering. Leerink Swann
LLC is acting as co-lead manager for the offering and Griffin Securities, Inc. is acting as
co-manager for the offering.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any
securities of Unilife, nor shall there be any sale of securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. This press release is being issued
pursuant to and in accordance with Rule 134 of the Securities Act of 1933, as amended.
A shelf registration statement relating to the shares was filed with the Securities and Exchange
Commission and is effective. A preliminary prospectus supplement related to the offering has been
filed with the Securities and Exchange Commission (SEC) and a final prospectus supplement will be
filed with the SEC and will be available on the SECs website located at www.sec.gov. When
available, copies of the final prospectus supplement relating to this offering may be obtained from
Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor,
New York, NY, 10022, at 877-547-6340, and at Prospectus_Department@Jefferies.com.
About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of
a diversified portfolio of advanced drug delivery systems. Unilife collaborates with
pharmaceutical and biotechnology companies seeking to optimize drug lifecycles and generate
differentiation for their brand in competitive therapeutic markets through the use of innovative
devices that can improve patient care, protect healthcare workers and prevent disease. Unilife has
developed a broad portfolio of drug delivery systems in direct response to unmet market needs for
macromolecule injectable drugs including biologics.
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
Safe Harbor Statement
This press release contains forward-looking statements. All statements that address operating
performance, events or developments that we expect or anticipate will occur in the future are
forward-looking statements. These forward-looking statements are based on managements beliefs and
assumptions and on information currently available to our management. Our management believes that
these forward-looking statements are reasonable as and when made. However, you should not place
undue reliance on any such forward-looking statements because such statements speak only as of the
date when made. We do not undertake any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required
by law. In addition, forward-looking statements are subject to certain risks and uncertainties that
could cause actual results, events and developments to differ materially from our historical
experience and our present expectations or projections. These risks and uncertainties include, but
are not limited to, those described in Item 1A. Risk Factors and elsewhere in our Annual Report
on Form 10-K, in the final prospectus supplement and related prospectus relating to the offering
and those described from time to time in other reports which we file with the Securities and
Exchange Commission.
General: UNIS-G
Investor Contacts (US):
|
Investor Contacts (Australia) | |||
Todd Fromer / Garth Russell
|
Stuart Fine | Jeff Carter | ||
KCSA Strategic Communications
|
Carpe DM Inc | Unilife Corporation | ||
P: + 1 212-682-6300
|
P: + 1 908 469 1788 | P: + 61 2 8346 6500 |